Efficacy and Safety of Humanized Anti-Cd19-Car-T Therapy Following Intensive Lymphodepleting Chemotherapy for Refractory/Relapsed B Acute Lymphoblastic Leukaemia

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.16623
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Potent Anti-Leukemia Activities of Humanized CD19-targeted CAR-T Cells in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2018English

CTL019 (Tisagenlecleucel): CAR-T Therapy for Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

CAR-T Cells and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Immunotherapy
OncologyAllergyImmunology
2017English

CAR T Cell Therapy in B-Cell Acute Lymphoblastic Leukaemia: Insights From Mathematical Models

2020English

Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Intensive Consolidation Chemotherapy for Acute Lymphoblastic Leukaemia (UKALL X Pilot Study).

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
1987English

Locally Produced CD19 CAR T Cells Leading to Clinical Remissions in Medullary and Extramedullary Relapsed Acute Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2018English

An Effective Modestly Intensive Re-Induction Regimen With Bortezomib in Relapsed or Refractory Paediatric Acute Lymphoblastic Leukaemia

British Journal of Haematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy